NASDAQ
ADRX
Last Price
US $14.2
KEY FIGURES
MKT CAP
$1.6B
EPS
TTM$-0.90
EPS Growth (1Y)
-
PEG
TTMN/M
P/E
TTMN/M
P/S
TTM-
YIELD
—
GROWTH (5Y CAGR)
Revenue
-
EBITDA
-
Cash flow
Valuation
Financial
Performance
Cash flow to debt coverage
ADARx Pharmaceuticals, Inc. cash flow to debt ratio of 3.39K% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Free cash flow growth
ADARx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Debt-to-equity ratio
ADARx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Debt-to-equity trend
ADARx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Net debt to EBITDA
ADARx Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.
Interest coverage
ADARx Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Profit margin growth
ADARx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Current ratio
ADARx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Return on assets
ADARx Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
ADARx Pharmaceuticals, Inc.'s return on equity of 368.00%, is higher than 15.00%, indicating good performance
Earnings quality
ADARx Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
ADARx Pharmaceuticals, Inc. has insufficient public price history to evaluate earnings stability.
Positive free cash flow
ADARx Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Free cash flow yield
ADARx Pharmaceuticals, Inc. has a free cash flow yield of 16.49%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Earnings growth
ADARx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Revenue growth
ADARx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Return on invested capital
ROIC -12.83% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
ADARx Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.
Revenue consistency
ADARx Pharmaceuticals, Inc. has insufficient public price history to evaluate revenue consistency.
Return on equity consistency
ADARx Pharmaceuticals, Inc. has insufficient public price history to evaluate ROE consistency.
Base Cash Flow Valuation (DCF)
ADARx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
Earnings yield (TTM)
ADARx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Base EBITDA Valuation
ADARx Pharmaceuticals, Inc. has insufficient data to evaluate this check.
EV/EBITDA (FY)
ADARx Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
ADARx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
ADARx Pharmaceuticals, Inc. has a price-to-book ratio of 2.65x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Price-to-sales ratio (TTM)
ADARx Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
368%
Return on equity
ROIC: -12.83%
Valuation History
-
Price to Earnings
EV/EBITDA: -9.1X
Cash flow
Profit margin
-
Fair Value
Market $14.2
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.